Tweet
Int Immunopharmacol. 2020 Apr 2;83:106455. doi: 10.1016/j.intimp.2020.106455. [Epub ahead of print]
The possible of immunotherapy for COVID-19: A systematic review.
AminJafari A1, Ghasemi S2.
Author information
Abstract
The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstratedthat although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option.
Copyright ? 2020 Elsevier B.V. All rights reserved.
KEYWORDS:
2019-nCoV; COVID-19; Immunotherapy; Interleukin; Monoclonal antibody; Vaccine
PMID:32272396DOI:10.1016/j.intimp.2020.106455